<?xml version='1.0' encoding='utf-8'?>
<document id="32076889"><sentence text="A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males."><entity charOffset="52-57" id="DDI-PubMed.32076889.s1.e0" text="urate" /><entity charOffset="136-145" id="DDI-PubMed.32076889.s1.e1" text="oxaprozin" /><pair ddi="false" e1="DDI-PubMed.32076889.s1.e0" e2="DDI-PubMed.32076889.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32076889.s1.e0" e2="DDI-PubMed.32076889.s1.e1" /></sentence><sentence text="Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by inhibiting the urate transporter 1"><entity charOffset="32-37" id="DDI-PubMed.32076889.s2.e0" text="urate" /><entity charOffset="82-91" id="DDI-PubMed.32076889.s2.e1" text="uric acid" /><entity charOffset="117-122" id="DDI-PubMed.32076889.s2.e2" text="urate" /><pair ddi="false" e1="DDI-PubMed.32076889.s2.e0" e2="DDI-PubMed.32076889.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32076889.s2.e0" e2="DDI-PubMed.32076889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32076889.s2.e0" e2="DDI-PubMed.32076889.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32076889.s2.e1" e2="DDI-PubMed.32076889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32076889.s2.e1" e2="DDI-PubMed.32076889.s2.e2" /></sentence><sentence text=" The results of nonclinical studies indicated the possibility that the concomitant use of the non-steroidal anti-inflammatory drug oxaprozin affects the pharmacokinetics of dotinurad"><entity charOffset="131-140" id="DDI-PubMed.32076889.s3.e0" text="oxaprozin" /><entity charOffset="173-182" id="DDI-PubMed.32076889.s3.e1" text="dotinurad" /><pair ddi="false" e1="DDI-PubMed.32076889.s3.e0" e2="DDI-PubMed.32076889.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32076889.s3.e0" e2="DDI-PubMed.32076889.s3.e1" /></sentence><sentence text=" We evaluated drug-drug interactions with respect to the pharmacokinetics and safety of dotinurad when co-administered with oxaprozin"><entity charOffset="124-133" id="DDI-PubMed.32076889.s4.e0" text="oxaprozin" /></sentence><sentence text="" /><sentence text="This was an open-label, two-period, add-on study in healthy adult males" /><sentence text=" For a single dose of 4Â mg of dotinurad with and without oxaprozin, we compared its pharmacokinetic parameters and evaluated safety"><entity charOffset="57-66" id="DDI-PubMed.32076889.s7.e0" text="oxaprozin" /></sentence><sentence text="" /><sentence text="This study enrolled 12 subjects, 11 of whom completed the study" /><sentence text=" The geometric mean ratio (90% confidence interval [CI]) of the urinary excretion rate of glucuronate conjugates of dotinurad after co-administration with oxaprozin compared to administration of dotinurad alone was 0"><entity charOffset="90-101" id="DDI-PubMed.32076889.s10.e0" text="glucuronate" /><entity charOffset="155-164" id="DDI-PubMed.32076889.s10.e1" text="oxaprozin" /><pair ddi="false" e1="DDI-PubMed.32076889.s10.e0" e2="DDI-PubMed.32076889.s10.e0" /><pair ddi="false" e1="DDI-PubMed.32076889.s10.e0" e2="DDI-PubMed.32076889.s10.e1" /></sentence><sentence text="657 (0" /><sentence text="624-0" /><sentence text="692), while the geometric mean ratios (90% CIs) of the maximum plasma concentration and area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) were 0" /><sentence text="982 (0" /><sentence text="945-1" /><sentence text="021) and 1" /><sentence text="165 (1" /><sentence text="114-1" /><sentence text="219), respectively" /><sentence text=" During the study, two adverse events occurred after administration of dotinurad alone and one occurred after administration of oxaprozin alone"><entity charOffset="128-137" id="DDI-PubMed.32076889.s20.e0" text="oxaprozin" /></sentence><sentence text="" /><sentence text="In comparison with administration of dotinurad alone, co-administration with oxaprozin was associated with a 34"><entity charOffset="77-86" id="DDI-PubMed.32076889.s22.e0" text="oxaprozin" /></sentence><sentence text="3% decrease in the urinary excretion rate of the glucuronate conjugates of dotinurad, and a 16"><entity charOffset="49-60" id="DDI-PubMed.32076889.s23.e0" text="glucuronate" /><entity charOffset="75-84" id="DDI-PubMed.32076889.s23.e1" text="dotinurad" /><pair ddi="false" e1="DDI-PubMed.32076889.s23.e0" e2="DDI-PubMed.32076889.s23.e0" /><pair ddi="false" e1="DDI-PubMed.32076889.s23.e0" e2="DDI-PubMed.32076889.s23.e1" /></sentence><sentence text="5% increase in AUC0-inf of dotinurad" /><sentence text=" However, no clinically meaningful drug-drug interactions were observed" /><sentence text=" Administration of dotinurad alone was similar safety to co-administration with oxaprozin"><entity charOffset="80-89" id="DDI-PubMed.32076889.s26.e0" text="oxaprozin" /></sentence><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov Identifier: NCT03350386" /><sentence text="" /></document>